Bausch + Lomb's Q1 Likely Saw Revenue Tailwinds From ForEx, RBC Says

MT Newswires Live

04/24

Bausch + Lomb's (BLCO) Q1 likely saw revenue tailwinds from foreign exchange, continuing trends from Q4, RBC Capital Markets said in a Thursday note.

Broad currency strength, compared with the US dollar, is estimated to have yielded about a $40 million revenue benefit in Q1 and will likely add about $70 million for all of 2026, RBC said. The company's 2026 revenue guidance currently calls for a $30 million FX tailwind, RBC said.

Bausch + Lomb is set to report its Q1 results on April 29 and investors are expected to focus on the company's primary prescription for dry eye disease products, the investment firm added. RBC said investor concerns include Miebo's profitability in 2026 and Xiidra's net pricing improvement.

RBC has an outperform rating on Bausch + Lomb, with a $21 price target.

Price: 15.75, Change: -0.03, Percent Change: -0.19

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2629669825"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629669825\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629669825?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 23:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629669825","market":"sg","top_or_hot":-1,"title":"Bausch + Lomb's Q1 Likely Saw Revenue Tailwinds From ForEx, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Bausch + Lomb's (BLCO) Q1 likely saw revenue tailwinds from foreign exchange, continuing trends from Q4, RBC Capital Markets said in a Thursday note.</p><p>Broad currency strength, compared with the US dollar, is estimated to have yielded about a $40 million revenue benefit in Q1 and will likely add about $70 million for all of 2026, RBC said. The company's 2026 revenue guidance currently calls for a $30 million FX tailwind, RBC said.</p><p>Bausch + Lomb is set to report its Q1 results on April 29 and investors are expected to focus on the company's primary prescription for dry eye disease products, the investment firm added. RBC said investor concerns include Miebo's profitability in 2026 and Xiidra's net pricing improvement.</p><p>RBC has an outperform rating on Bausch + Lomb, with a $21 price target.</p><p>Price: 15.75, Change: -0.03, Percent Change: -0.19</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch + Lomb's Q1 Likely Saw Revenue Tailwinds From ForEx, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch + Lomb's Q1 Likely Saw Revenue Tailwinds From ForEx, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-24 23:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bausch + Lomb's (BLCO) Q1 likely saw revenue tailwinds from foreign exchange, continuing trends from Q4, RBC Capital Markets said in a Thursday note.</p><p>Broad currency strength, compared with the US dollar, is estimated to have yielded about a $40 million revenue benefit in Q1 and will likely add about $70 million for all of 2026, RBC said. The company's 2026 revenue guidance currently calls for a $30 million FX tailwind, RBC said.</p><p>Bausch + Lomb is set to report its Q1 results on April 29 and investors are expected to focus on the company's primary prescription for dry eye disease products, the investment firm added. RBC said investor concerns include Miebo's profitability in 2026 and Xiidra's net pricing improvement.</p><p>RBC has an outperform rating on Bausch + Lomb, with a $21 price target.</p><p>Price: 15.75, Change: -0.03, Percent Change: -0.19</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLCO","symbol_name":"博士伦","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2629669825","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629669825","pubTimestamp":1777045171,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bausch + Lomb's  Q1 likely saw revenue tailwinds from foreign exchange, continuing trends from Q4, RBC Capital Markets said in a Thursday note.Broad currency strength, compared with the US dollar, is estimated to have yielded about a $40 million revenue benefit in Q1 and will likely add about $70 million for all of 2026, RBC said. The company's 2026 revenue guidance currently calls for a $30 million FX tailwind, RBC said.Bausch + Lomb is set to report its Q1 results on April 29 and investors are expected to focus on the company's primary prescription for dry eye disease products, the investment firm added. RBC said investor concerns include Miebo's profitability in 2026 and Xiidra's net pricing improvement.RBC has an outperform rating on Bausch + Lomb, with a $21 price target.Price: 15.75, Change: -0.03, Percent Change: -0.19","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLCO":"博士伦","BK4198":"医疗保健用品"},"translate_title":"加拿大皇家银行表示，博士伦第一季度的收入可能会受到外汇的推动","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLCO":1},"content_text":"Bausch + Lomb's (BLCO) Q1 likely saw revenue tailwinds from foreign exchange, continuing trends from Q4, RBC Capital Markets said in a Thursday note.Broad currency strength, compared with the US dollar, is estimated to have yielded about a $40 million revenue benefit in Q1 and will likely add about $70 million for all of 2026, RBC said. The company's 2026 revenue guidance currently calls for a $30 million FX tailwind, RBC said.Bausch + Lomb is set to report its Q1 results on April 29 and investors are expected to focus on the company's primary prescription for dry eye disease products, the investment firm added. RBC said investor concerns include Miebo's profitability in 2026 and Xiidra's net pricing improvement.RBC has an outperform rating on Bausch + Lomb, with a $21 price target.Price: 15.75, Change: -0.03, Percent Change: -0.19","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}